This trial is withdrawn!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Acute Myocardial Infarction, ST Elevation Myocardial Infarction or STEMI
and you are
between 18 and 75
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

The objective of this study is to evaluate the safety and tolerability of two active doses of RGN-352 (thymosin beta 4, Tβ4, Injectable Solution) in patients with acute myocardial infarction receiving percutaneous coronary intervention angioplasty with or without stent placement. Approximately 75 subjects will be randomized to receive one of two RGN-352 doses of 1200 mg, or 450 mg, or placebo, administered iv by iv push daily for the first 3 consecutive days and weekly for 4 more weeks.

Provided treatments

  • Drug: Drug: Placebo
  • Drug: Drug: Injectable Thymosin beta 4

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01311518. The sponsor of the trial is RegeneRx Biopharmaceuticals, Inc. and it is looking for 0 volunteers for the current phase.
Official trial title:
A Randomized, Double-blind, Placebo-Controlled, Study of the Safety and Efficacy of RGN-352 in Subjects With an Acute ST Elevation Myocardial Infarction (STEMI) After Occlusion of the Proximal Left Anterior Descending Coronary Artery